PAMAM dendrimers and prospects of their application in medicine
- 30 March 2022
- journal article
- review article
- Published by Federal Medical Biological Agency
- No. 2022(1)
Abstract
Development of drug delivery systems based on branched biocompatible polymers is one of the most promising areas of modern nanopharmaceutics. Researchers have been exploring this area several decades now, and the results of their efforts quickly find their way into production. Dendrimers, a new class of universal synthetic polymers with a highly functional surface, have a number of unique properties: constant size, high degree of branching, multivalence, solubility in water, definite molecular weight, internal cavities. With the release of VivaSol gel, the first dendrimer-based commercialized product, the "model range" of dendrimer carriers has grown significantly. Poly(amide-amine) (PAMAM) dendrimers, which consist of an alkyldiamine core and tertiary amine branches, are believed to be among the most promising compounds that can be used in the development of the new generation drugs. However, they were kept out of the list of clinically acceptable compounds for a long time because of their toxicity, unclear behavior in living systems and pharmacokinetic profile, as well the difficulties associated with establishing a therapeutic dose. This review presents basic information about PAMAM dendrimers and attempts to assess the prospects of their application in treatment of various diseases, including COVID-19.Keywords
This publication has 46 references indexed in Scilit:
- KE108-conjugated unimolecular micelles loaded with a novel HDAC inhibitor thailandepsin-A for targeted neuroendocrine cancer therapyBiomaterials, 2016
- Dexamethasone‐Conjugated Polyamidoamine Dendrimer for Delivery of the Heme Oxygenase‐1 Gene into the Ischemic BrainMacromolecular Bioscience, 2015
- Arginine modified PAMAM dendrimer for interferon beta gene delivery to malignant gliomaInternational Journal of Pharmaceutics, 2013
- Evidence of Oral Translocation of Anionic G6.5 Dendrimers in MiceMolecular Pharmaceutics, 2013
- In vivo efficacy of dendrimer–methylprednisolone conjugate formulation for the treatment of lung inflammationInternational Journal of Pharmaceutics, 2010
- Co-delivery of as-miR-21 and 5-FU by Poly(amidoamine) Dendrimer Attenuates Human Glioma Cell Growth in VitroJournal of Biomaterials Science, Polymer Edition, 2010
- Anti-inflammatory and anti-oxidant activity of anionic dendrimer–N-acetyl cysteine conjugates in activated microglial cellsInternational Journal of Pharmaceutics, 2009
- Poly(amidoamine) dendrimer–drug conjugates with disulfide linkages for intracellular drug deliveryBiomaterials, 2009
- A PEGylated dendritic nanoparticulate carrier of fluorouracilInternational Journal of Pharmaceutics, 2003
- Dendrimers, a New Class of Candidate Topical Microbicides with Activity against Herpes Simplex Virus InfectionAntimicrobial Agents and Chemotherapy, 2000